Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 2, 2007, Pages

  Jones, Steven M ^a,d   Ströher, Ute ^a   Fernando, Lisa ^a   Qiu, Xianggou ^a   Alimonti, Judie ^a   Melito, Pasquale ^a   Bray, Mike ^b   Klenk, Hans Dieter ^c   Feldmann, Heinz ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VECTOR; VIRUS GLYCOPROTEIN; VIRUS VECTOR; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EBOLA VIRUS; MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VESICULAR STOMATITIS VIRUS; VIRUS HEMORRHAGIC FEVER; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DISEASE MODEL; FEMALE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; VIRUS CULTURE;

ANIMALS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; MICE; MICE, INBRED BALB C; PLAQUE ASSAY; VESICULOVIRUS; VIRAL VACCINES;

EID: 38449103068     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520591     Document Type: Conference Paper

References (48)

1. Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003; 3:677-85.
2. Centers for Disease Control and Prevention. Bioterrorism agents/diseases. Available at: http://www.bt.cdc.gov/Agent/Agentlist.asp. Accessed 11 October 2007.
3. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287:2391-405.
4. Jaax NK, Davis KJ, Geisbert TJ, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120:140-55.
5. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995;76:227-36.
6. Bazhutin NB, Belanov EF, Spiridonov VA, et al. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys [in Russian]. Vopr Virusol 1992; 37:153-6.
7. Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines 2003; 2:777-89.
8. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7.
9. Hart MK. Vaccine research efforts for filoviruses. Int J Parasitol 2003; 33:583-95.
10. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
11. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4.
12. Chirmule N, Propert K, Magosin S, Qian Y, Qian R,Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6:1574-83.
13. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1994; 1:395-402.
14. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996; 3:154-62.
15. Letvin NL, Huang Y, Chakrabarti BK, et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78:7490-7.
16. Ophorst OJ, Kostense S, Goudsmit J, et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004; 22:3035-44.
17. Reyes-Sandoval A, Fitzgerald JC, Grant R, et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 2004; 78:7392-9.
18. Wagner RR, Rose JK. Rhabdoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. 3rd ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 1996:1121-59.
19. Zinkernagel RM, Adler B, Holland JJ. Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp Cell Biol 1978; 46:53-70.
20. Roberts A, Kretzschmar E, Perkins AS, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998; 72:4704-11.
21. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999; 73:3723-32.
22. Schlereth B, Rose JK, Buonocore L, ter Meulen V, Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 2000; 74:4652-7.
23. Grigera PR, Marzocca MP, Capozzo AV, Buonocore L, Donis RO, Rose JK. Presence of bovine viral diarrhea virus (BVDV) E2 glycoprotein in VSV recombinant particles and induction of neutralizing BVDV antibodies in mice. Virus Res 2000; 69:3-15.
24. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 2001; 75:11079-87.
25. Buonocore L, Blight KJ, Rice CM, Rose JK. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 2002; 76:6865-72.
26. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106:539-49.
27. Garbutt M, Liebscher R,Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65.
28. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659-66.
29. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005; 2:e183.
30. Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
31. Daddario-DiCaprio KM, Geisbert TW, Ströher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399-404.
32. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
33. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
34. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA 1996; 93:11359-65.
35. Bullifent HL, Griffin KF, Jones SM, Yates A, Harrington L, Titball RW. Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters. Vaccine 2000; 18:2668-76.
36. Wahl-Jensen V, Kurz SK, Hazelton PR, et al. The role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005; 79:2413-9.
37. Jahrling PB. Filoviruses and arenaviruses. In: Murray PR, ed. Manual of clinical microbiology. Washington, DC: ASM Press, 1999:1125-36.
38. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(Suppl 1):S224-34.
39. Cobbold SP, Martin G, Qin S, Waldmann H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986; 323:164-6.
40. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125:243-53.
41. Gibb TR, Bray M, Geisbert TW, et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 2001; 125:233-42.
42. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol 2001; 75:4649-54.
43. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76:6408-12.
44. Gupta M, Mahanty S, Greer P, et al. Persistent infection with Ebola virus under conditions of partial immunity. J Virol 2004; 78:958-67.
45. Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007; 360:36-49.
46. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80:148-58.
47. Leroy EM, Rouquet P, Formenty P, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004; 303:387-90.
48. Vogel G. Conservation biology: can great apes be saved from Ebola? Science 2003; 300:1645.